Articles tagged with Human Immunodeficiency Virus
The UK's HIV strategy is being heavily criticized due to its inadequate approach to testing and diagnosis. An estimated 77,000 people are living with HIV in the UK, with 21,000 unaware of their positive status. A third of those diagnosed late could have benefited from treatment if identified earlier.
A recent study has mapped the spread of HIV-1 subtype B across Europe, revealing that popular tourist destinations like Greece, Portugal, and Spain are major sources of infection. The research found that viruses can be transmitted through travelers, highlighting the need for targeted prevention efforts beyond national borders.
A research team led by Andrew Barron at Rice University identified specific molecules that can block the spread of HIV-1 PR by attaching themselves to its binding pocket. They used computer simulations to narrow down a collection of fullerenes and found two promising candidates.
Research reveals that HIV-positive individuals are more susceptible to lung-related problems and experience a swifter decline in lung function compared to their HIV-negative counterparts. The study also found that HIV-positive smokers are at risk of developing early emphysema.
A recent clinical trial found that acyclovir, a widely used herpes treatment, did not reduce the risk of HIV transmission when taken by individuals with both HIV and HSV-2. However, the study did show a significant reduction in genital ulcers and modest decrease in HIV levels.
Pediatric experts from Children's National Medical Center presented innovative research on urban health issues, HIV, and childhood obesity. The studies highlighted the importance of universal rapid HIV screening for teens in pediatric EDs and the impact of second-hand tobacco smoke on children.
Researchers estimated virus evolution using genetic sequences and found that SIV lineages giving rise to HIV-1 and HIV-2 date back to the 18th century. This finding challenges previous estimates of millions of years of coevolution between SIVs and their primate hosts.
Scientists at the University of Central Florida have revived a dormant gene found in humans, which produces retrocyclin, a protein that resists HIV. The study found that restoring the production of retrocyclins prevents HIV entry and transmission.
Two studies show that adult circumcision reduces the risk of contracting HIV and coital injuries, but does not affect sexual function. Circumcision removes skin surface susceptible to HIV infection, reducing the risk of transmission.
The UCSF Visiting Professor Program has provided training and mentoring to 40 visiting professors from minority universities, resulting in over $50 million in research funding and 425 scientific publications. The program accelerates careers and promotes interdisciplinary approaches to HIV/AIDS prevention research.
Researchers found that HIV antibodies face obstacles in blocking infection, with a narrow window of opportunity for effective binding due to the virus's low spike density. This finding highlights potential challenges for developing an effective vaccine against HIV.
Researchers discover HIV counteracts human cell protection by marking proteins for rapid destruction, but not in rats. Disrupting this interaction could be a promising strategy for therapy to increase cells' protective mechanisms.
Researchers found that HIV's invisibility comes at a cost: reduced replication, and only in certain individuals with specific HLA proteins
A new study analyzing over 45,000 people with HIV in Europe and North America found that starting combination antiretroviral therapy (cART) at a minimum CD4-cell count of 350 cells per µL reduces AIDS-related events and death rates. The findings challenge current guidelines recommending cART initiation at a lower threshold.
A recent study found that HIV-positive patients are entering care with lower initial CD4 cell counts and often require antiretroviral therapy soon after diagnosis. The trend suggests the virus has become more virulent, with a significant increase in patients requiring treatment before reaching the threshold of 350 CD4 cells/mm³.
Researchers from University College London have developed a new device to enable people living with HIV to monitor their own health and treatment effectiveness. The device uses nano-cantilever arrays to measure HIV markers, providing patients with clear, immediate advice on their condition.
A Stanford study found that the US AIDS Relief program reduced HIV/AIDS death tolls by over 10% in targeted African countries, saving an estimated 1 million lives. However, there was no significant impact on disease prevalence rates.
A new study published in the New England Journal of Medicine found that starting antiretroviral treatment earlier can significantly increase survival rates among asymptomatic HIV patients. The research, led by Dr. Mari Kitahata at the University of Washington, analyzed data from over 17,500 patients and showed that delaying treatment u...
A potential new HIV drug, D-1mT, shows promise in reducing viral loads in monkeys with simian immunodeficiency virus when used alongside Anti-Retroviral Therapy. The researchers hope this finding could lead to a new treatment for patients not responding to current treatments.
Researchers found drug-resistant viruses can circulate between individuals who haven
Researchers have developed a new type of DNA with 12 chemical letters, enabling highly parallel amplification of DNA and diagnosis of human diseases. This breakthrough may shed light on the origins of life and personalization of medicine for millions of patients with HIV, hepatitis, and other diseases.
Researchers find suberoylanilide hydroxamic acid (SAHA) activates latent HIV in cells and blood samples, potentially improving upon HAART treatment. This breakthrough offers new hope for eradicating the virus.
A new study found that intermittent IL-7 therapy, combined with conventional antiretroviral therapy (c-ART), boosts the number of CD4+ and CD8+ T cells in HIV-infected patients with low T cell counts. This effect was observed for 48 weeks, suggesting a potential treatment option for these individuals.
Researchers at Rutgers University have made significant progress in developing an HIV vaccine by identifying a crucial part of the virus that is common to most varieties. They created a method to immunize animals with this target, resulting in antibodies that can stop a diverse set of HIV isolates.
Researchers at NYU College of Dentistry have been awarded a five-year grant to investigate the cooperative interactions between HIV viruses that aid in replication and disease persistence. The team aims to understand how these interactions speed up virus evolution, which could lead to new ways of slowing or stopping HIV replication.
Researchers at Stanford University School of Medicine have compiled a list of 93 common HIV mutations associated with drug resistance to track the spread of the virus. The updated list is based on data from over 15,000 patients and will be used globally to gauge the effectiveness of HIV medication programs.
Leading scientists issue a challenge to find a way to purge latent HIV infection and eliminate the need for chronic therapy. A drug-free remission goal requires understanding of persistent infection reservoirs and combination approaches.
Researchers have successfully infected pig-tailed macaques with a human version of HIV, creating an animal model for studying prevention methods. The new strain, simian-tropic HIV-1 (stHIV-1), can spread almost as quickly as in humans and persists for several months.
A new study compares cholesterol treatment in HIV patients and those without HIV, finding that lipid-lowering therapies are effective but not as effective as in non-HIV patients. The study suggests using fibrates with NNRTIs to manage triglyceride levels in HIV patients.
Researchers analyzed genetic data from over 2,800 HIV-infected patients to identify 14 'escape mutations' that help the virus survive. These mutations allow the virus to evade the immune system's destruction, making it challenging to develop effective AIDS vaccines.
Research in Cameroon reveals that 88.3% of women are willing to accept HIV testing during labor, leading to a higher rate of detected infections compared to previously estimated rates. The study recommends an opt-out approach for HIV testing during labor to increase the number of mother-infant pairs receiving appropriate treatment.
Dr. Sara Sawyer will use a $120,000 grant to study how HIV and its host cells have evolved together over time. By analyzing the genomes of primates, she aims to identify critical genes and proteins that could lead to new antiviral drug targets.
A new study found that gene therapy can be developed as a potentially effective treatment for HIV, reducing viral load and preserving the immune system. The technique involves delivering genes to cells to prevent viral replication, with promising results in a clinical trial involving 74 HIV-positive adults.
A new study reveals that the majority of US states have laws consistent with or neutral toward the CDC's revised HIV testing guidelines. Despite concerns about opt-out screening, the study finds protections for patient autonomy are not required by state laws in many cases.
The study solved the structure of a biological protein from the vaccinia virus, providing insights into its relationships with other viruses. This discovery is significant as it can help develop new therapies to treat various viruses, offering potential solutions to outbreaks and pandemics.
A UK survey found that only 30% of mental health workers discuss sexual health issues with service users, despite 80% agreeing it's an important part of their role. The study also revealed low levels of awareness about HIV risks among people with schizophrenia, leading to concerns about infection rates and staff safety.
Population immunity to measles was insufficient to interrupt transmission three years after a mass vaccination campaign in Zambia. Repeated mass vaccination campaigns are necessary to achieve high routine vaccine coverage and reduce measles deaths and illness.
A five-year Canadian study led by Dr. Cécile Tremblay aims to develop new strategies to fight AIDS in individuals who naturally control their HIV infection progression. The study will analyze factors predicting favourable outcomes and identify drivers of HIV diversity.
A variant of the protein Nef has been identified as a potential target for HIV treatment, with the goal of suppressing its production to prevent AIDS progression. Researchers believe that a drug affecting Nef could provide protection against the virus and complement existing therapies.
A team of researchers highlights challenges and concerns with unlinked anonymous HIV testing in developing countries. They outline strategies to harmonize high-quality surveillance with international ethical standards, including reviewing justifications, providing confidential voluntary testing, and strengthening local capacity.
A Johns Hopkins study found that HIV-positive kidney transplant recipients can achieve one-year survival rates comparable to those without HIV, provided key risk factors for transplant failure are recognized and controlled. The study's results reflect the impact of newer antiretroviral therapies on reducing HIV-related deaths.
Scientists have identified a critical element in HIV pathogenesis: the translational control of HIV-1 RNA in the cytoplasm. A Sam68 mutant suppresses Nef expression by sequestering nef mRNA, offering a new strategy for developing anti-HIV therapeutics.
A study published in Blood journal reveals that individuals with rare blood type Pk are more resistant to HIV infection, while those without it are more susceptible. This discovery paves the way for new therapeutic approaches to induce HIV resistance and promote further understanding of the pandemic.
Prisons have high-risk environments for HIV transmission due to needle-sharing. Implementing needle/syringe programs (NSPs) and opioid substitution therapy (OST) can reduce risky behavior, overdose deaths, and improve relationships between prisoners and staff. These measures are essential for protecting prisoners' health.
A new study found that circumcision significantly reduced HIV infection risk in heterosexual African American men with known exposure. The study's findings complement previous research on adult male circumcision in Africa.
HIV can infect immune cells in a woman's vaginal tract through the skin, not just through breaks or lesions. The virus penetrates healthy genital skin to reach its targets within four hours.
Researchers have identified broad-spectrum aptamers that can treat many subtypes of HIV-1 by inhibiting reverse transciptase. These synthetic molecules can reduce viral infectivity and block the normal action of RT enzyme.
Scientists at Northwestern University found that HIV can penetrate female genital tissue by moving quickly between skin cells, allowing the virus to reach immune cells. This discovery challenges the long-held assumption that the female genital tract is an efficient barrier to viral penetration.
A new study found that HIV's rate of evolution slows significantly when a patient's CD4+ T-cell count drops, which can happen long before symptoms of AIDS appear. This change allows the immune system to keep up with the virus, potentially making it harder for it to develop resistance to treatment.
A study of 1833 HIV patients found that specific mitochondrial DNA genotypes accelerate AIDS development, while others delay it. This suggests that genetic tests could provide accurate prognoses and guide early treatment initiation.
The American College of Physicians recommends that physicians adopt a routine screening policy for HIV, encouraging patients to get tested regardless of risk factors. Timely identification of undiagnosed cases can help prevent HIV transmission.
Researchers at Penn State have discovered that increasing selenium levels in human blood cells can reduce the multiplication of the AIDS virus. By targeting a specific protein called Tat, selenium can slow down viral replication, with results showing a 10-fold decrease.
A WHO study suggests that universal voluntary HIV testing combined with immediate treatment after diagnosis could significantly reduce HIV cases in a severe epidemic. The strategy aims to accelerate the transition from an endemic phase to an elimination phase, reducing HIV cases to 1 per 1000 people within 10 years.
A landmark study found that early HIV testing and treatment in infants significantly improves survival rates, reducing mortality by 75% and HIV-related disease by four times. The study's results led to the World Health Organization's new guidelines for treating HIV-infected infants under age 1 immediately after diagnosis.
A meta-analysis published by the American Association for Cancer Research found that individuals with HIV have a higher risk of non-AIDS cancers compared to the general population. The risk is significantly higher for men than women, and incidence rates are similar between those with AIDS and without.
A study by Associate Professor Katherine Samaras reveals that HIV treatment causes inflammation, leading to increased cardiac and metabolic risk. Patients with HIV-infection tend to gain weight around their abdomen, increasing their risk of heart disease and diabetes.
Scientists discovered a key step in HIV's attack on brain cells and were able to reverse its effects by blocking the receptor. The discovery opens up a new avenue for researchers to explore in preventing or treating HIV's neurological effects, which have no currently approved treatment.
Scientists have identified a crucial role for sulfonation in HIV replication, finding that inhibiting this pathway can compromise viral gene expression and render host cells resistant to infection. This discovery provides a promising new target for HIV/AIDS therapy.
Researchers at UCLA discovered a chemical called TAT2 that can prevent or slow telomere shortening in immune cells, potentially making it a key weapon in the fight against HIV. The study found that TAT2 treatment prolonged the ability of killer T-cells to divide and inhibited HIV production.
Researchers have engineered killer T-cells with a receptor that can recognize and destroy HIV-infected cells, regardless of the virus's disguise. This technology may lead to a powerful therapy for HIV treatment and could also be applied to other infectious agents.